Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that the United States Supreme Court denied CareDx, Inc.’s (NASDAQ: CDNA) petition for certiorari concerning a patent infringement lawsuit brought by CareDx against Natera. This decision confirms the invalidity of the patents asserted against Natera and follows three previous rulings on the matter:

1. A September 2021 decision by the United States District Court for the District of Delaware, affirming that all three CareDx patents asserted against Natera were invalid for claiming patent-ineligible subject matter.
2. A June 2022 decision by the United States Court of Appeals for the Federal Circuit, affirming the Delaware Court’s decision.
3. A December 2022 denial of rehearing by the United States Court of Appeals for the Federal Circuit.

This final decision by the Supreme Court rejects the request by CareDx to litigate this matter once again and effectively terminates any existing claims brought by CareDx against Natera concerning these patents.

https://www.businesswire.com/news/home/20231003906151/en/